A Phase IIa trial, known as COURSE, has assessed the effectiveness of TEZSPIRE (tezepelumab) in reducing COPD exacerbations in patients with varying eosinophil counts. TEZSPIRE showed a notable reduction in exacerbations among patients with higher eosinophil counts.
Overall, TEZSPIRE led to a 17% numerical decrease in exacerbations compared to placebo, although it was not statistically significant. In patients with eosinophil counts above 150 cells/µL, TEZSPIRE resulted in a 37% reduction in exacerbations, while those with eosinophil counts above 300 cells/µL experienced a 46% reduction.
Subgroup analysis revealed improved lung function and quality of life in patients receiving TEZSPIRE, particularly those with higher eosinophil counts. Safety and tolerability were comparable to TEZSPIRE’s approved severe asthma indication, with worsening COPD and COVID-19 infections being the most common adverse events.
These findings hold promise for the potential of TEZSPIRE in managing COPD across a wide range of patients, irrespective of emphysema, chronic bronchitis, or smoking history. Phase III trials are underway to evaluate TEZSPIRE’s efficacy in COPD further.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
